PREDICTABILITY AND SUSTAINABILITY ARE FUNDAMENTAL TO PROACTIVE GLAUCOMA SURGERY1-4

Hear it from your peers

Current glaucoma surgery methods can be effective, but variability of results remains an issue.2-4

What is your experience?

Answer a question and see how your response matches up with your peers’

What would best enable you to surgically intervene earlier when your glaucoma patients remain uncontrolled despite maximally tolerated medical therapy?

Between earlier detection and increasing lifespans, glaucoma prevalence is on the rise5,6

*Based on findings from the National Eye Institute and the Eye Diseases Prevalence Research Group.5,6

Graphic depicting findings from the National Eye Institute and the Eye Diseases Prevalence Research Group
Graphic depicting findings from the Mayo Clinic

Based on findings from the Mayo Clinic.7

Data in the US indicate that the current treatment paradigm is insufficient to arrest disease progression over a patient’s lifetime7

Proactive and aggressive management may result in better long-term outcomes and vision preservation8,9

The AGIS Study demonstrated that reaching low target IOP can successfully arrest glaucoma progression for at least 8 years.

Based on findings from the Advanced Glaucoma Intervention Study (AGIS) and the Tube Versus Trabeculectomy (TVT) Study.8-10

Graphic depicting findings from the AGIS and TVT Study

Further device innovation is needed to predictably and sustainably attain target IOP and to reduce or eliminate medication load over a patient’s lifetime.

References: 1. Chan JE, Netland PA. EX-PRESS Glaucoma Filtration Device: efficacy, safety, and predictability. Med Devices (Auckl). 2015;8:381-388. 2. Bloom P, Au L. “Minimally invasive glaucoma surgery (MIGS) is a poor substitute for trabeculectomy”—the great debate. Ophthalmol Ther. 2018;7(2):203-210. 3. Amoozgar B, Wei X, Lee JH, et al. A novel flexible microfluidic meshwork to reduce fibrosis in glaucoma surgery. PLoS One. 2017;12(3):e0172556. 4. Manasses DT, Au L. The new era of glaucoma micro-stent surgery. Ophthalmol Ther. 2016;5(2):135-146. 5. National Institutes of Health. National Eye Institute website. Glaucoma, open-angle tables. https://nei.nih.gov/eyedata/glaucoma/tables. Accessed July 21, 2019. 6. Friedman DS, Wolfs RC, O’Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538. 7. Hattenhauer MG, Johnson DH, Ing HH, et al. Probability of blindness from open-angle glaucoma. Ophthalmology. 1998;105(11):2099-2104. 8. Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495-505. 9. Gedde SJ, Schiffman JC, Feuer WJ, et al; Tube Versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) Study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803.e2. 10. Palmberg PF. The evolution of target pressure. Glaucoma Today. July/August 2014:33-35.

Receive updates from Santen on glaucoma surgical innovations and future training*

Receive updates from Santen on glaucoma surgical innovations and future training

Receive additional information from Santen on glaucoma surgical innovations. A representative from your region will be in touch.

All fields are required.

Information is missing in one or more fields.

Thank you for signing up!

You will receive an email confirming your registration.